WO2017125772A1 - Baricitinib salts - Google Patents
Baricitinib salts Download PDFInfo
- Publication number
- WO2017125772A1 WO2017125772A1 PCT/HU2017/050001 HU2017050001W WO2017125772A1 WO 2017125772 A1 WO2017125772 A1 WO 2017125772A1 HU 2017050001 W HU2017050001 W HU 2017050001W WO 2017125772 A1 WO2017125772 A1 WO 2017125772A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- baricitinib
- acid
- acetonitrile
- salt
- salts
- Prior art date
Links
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical class C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 title claims abstract description 116
- 229950000971 baricitinib Drugs 0.000 claims abstract description 107
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 40
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims abstract description 31
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940092714 benzenesulfonic acid Drugs 0.000 claims abstract description 12
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 11
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 abstract description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract description 8
- 239000013543 active substance Substances 0.000 abstract description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 abstract description 5
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001530 fumaric acid Substances 0.000 abstract description 5
- 235000006408 oxalic acid Nutrition 0.000 abstract description 5
- 235000002906 tartaric acid Nutrition 0.000 abstract description 4
- 239000011975 tartaric acid Substances 0.000 abstract description 4
- 229960000443 hydrochloric acid Drugs 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 162
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 39
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 28
- 239000002904 solvent Substances 0.000 description 23
- 239000011343 solid material Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000012265 solid product Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- 238000009835 boiling Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 239000000356 contaminant Substances 0.000 description 14
- 229960004592 isopropanol Drugs 0.000 description 13
- 238000001179 sorption measurement Methods 0.000 description 13
- 238000003860 storage Methods 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- -1 trifluoracetate ion Chemical class 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000013112 stability test Methods 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SRBRRMLIGZDAQK-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 SRBRRMLIGZDAQK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 2
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 2
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 2
- 101710133576 Slit homolog 2 protein Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical compound C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical class OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the subject of our invention relates to novel salts of the pharmaceutical active substance baricitinib, to a method for their production, to pharmaceutical preparations containing the novel salts as well as to the use of all these in medical therapy.
- baricitinib was first disclosed in international patent application number WO2009114512.
- the production of the baricitinib trifluoroacetate salt is described in example 1 of the patent application.
- the ⁇ -NMR and LC-MS data are given.
- the baricitinib trifluoroacetate salt is obtained using a preparative HPLC method. It should be noted that due to the toxic nature of the trifluoracetate ion it cannot be used as the counter ion of basic pharmaceutical active substances.
- the same patent application also discloses the baricitinib dihydrogen phosphate salt (incorrectly called phosphate in the application), and its production is also described.
- the dihydrogen phosphate salt is characterised by melting point, element analysis and with FTIR, 13 C-NMR, ⁇ NMR and LC-MS data.
- the patent application number WO 2015145286 describes the production of the amorphous form of the baricitinib base.
- the amorphous form is characterised by XRPD, DSC, TG, IR data.
- Patent application number WO 2015166434 describes the crystalline form of the baricitinib base containing 3% water.
- the crystalline form is characterised by XRPD, DSC, TG, IR data.
- the objective of elaborating the invention was the production of high-purity, new baricitinib salt forms with a homogenous crystalline structure, the stability and physical- chemical characteristics of which are preferable to those of the known forms and which have chemical stability at least as good and that of the known forms, and also which may be reproducibly produced even on industrial scales.
- the subject of the invention relates to new salts of ⁇ l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ⁇ i]pirimidin-4-yl)-lH-pyrazol- l-yl]azetidin-3-yl ⁇ acetonitrile with international non- proprietary name baricitinib that may be used as pharmaceutical active substances and a method for their production.
- the subject of the invention relates to the salts of baricitinib formed with ethanesulfonic acid (2), methanesulfonic acid (3) and benzenesulfonic acid (4), hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2- hydroxyethane sulfonic acid, fumaric acid, tartaric acid and cyclamic acid.
- the baricitinib tosylate salt form produced by us has a complex crystalline structure.
- the salt consists of several crystal forms, the thermodynamic stability of which may be very similar, as using the usual techniques it was not possible to achieve the desired solid phase inter- transformation and so the production of a homogenous, thermodynamically stable form.
- sulfonic acids especially ethanesulfonic acid (2), methanesulfonic acid (3) and benzenesulfonic acid (4) are forms with homogenous crystalline structures and may be reproducibly produced.
- Figure 1 The moisture sorption isotherms of baricitinib dihydrogen phosphate salt produced according to example 71 of international patent application number WO 2009114512 at 25 °C
- Figure 3 The moisture sorption isotherms of the baricitinib esylate (1:1) salt form at 25 °C
- Figure 4 The x-ray powder diffractogram of the baricitinib mesylate (1: 1) salt form
- the subject of the invention relates to the salts of baricitinib formed with sulfonic acids. More specifically, the subject of the invention is: - the baricitinib esylate (1: 1) salt,
- the subject of the invention relates to the crystalline baricitinib esylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2 ⁇ ( ⁇ 0.2 °2 ⁇ ): 5.80; 9.10; 13.57; 15.30; 18.30. More specifically it may be characterised by the following x-ray powder diffraction peaks: 2 ⁇ ( ⁇ 0.2 °2 ⁇ ): 5.80; 9.10; 11.59; 13.57; 15.30; 15.93; 18.30; 19.02; 20.09; 22.05.
- the moisture sorption isotherms of the baricitinib esylate (1: 1) salt form according to the invention recorded at 25 °C are presented in figure 3. It is visible that, preferably, the substance does not exhibit significant hygroscopicity. More specifically the subject of the invention also relates to the crystalline baricitinib mesylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2 ⁇ ( ⁇ 0.2 °2 ⁇ ): 5.84; 9.33; 13.92; 15.44; 18.59.
- the subject of the invention also relates to the crystalline baricitinib besylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2 ⁇ ( ⁇ 0.2 °2 ⁇ ): 7.19; 11.26; 12.63; 14.36; 16.51. More specifically it may be characterised by the following x-ray powder diffraction peaks: 2 ⁇ ( ⁇ 0,2 °2 ⁇ ): 7.19; 11.26; 12.63; 14.36; 16.51; 16.61; 17.66; 18.48; 20.83; 24.64.
- the 2.95 mg of ethanesulfonic acid, the 2.58 mg of methanesulfonic acid and the 4.25 mg of benzenesulfonic acid taken with the maximum daily dose of 10 mg of baricitinib is, preferably, just a fraction of the permitted daily amount of ethanesulfonic acid, methanesulfonic acid and benzenesulfonic acid, therefore toxicity concerns do not arise.
- the thermal stress test and the forced stability test present an accelerated model of the degradation occurring in the pharmaceutical preparation during storage.
- This preferable characteristic of the baricitinib salts according to the present invention is very important from the point of view of the formulation of the pharmaceutical preparation, its storage and the minimising of the damaging effects exerted on the human body.
- baricitinib esylate (1: 1), baricitinib mesylate (1: 1) and baricitinib besylate (1: 1) salts forming the subject of the present application was subjected to detailed tests.
- the baricitinib base was used as a reference.
- the results of the accelerated stability test are presented in the following tables 4 to 7.
- the table includes the percentage amounts of the contaminants and their change, as well the water content of the samples and its change.
- Table 4 The stability test data of the baricitinib base (1) used as a reference
- the baricitinib salts according to the present invention were seen to be especially stable as compared to the baricitinib base (1) and the baricitinib dihydrogen phosphate salt during 3 and 6 weeks of storage under various forced conditions.
- the salts (2-4) according to the present invention can be preferably produced at a greater level of purity than the reference baricitinib base (1).
- the salt forms preferably did not display water absorption under various storage conditions, even when the humidity was high. Therefore the baricitinib esylate (1: 1), baricitinib mesylate (1: 1) and baricitinib besylate (1: 1) salts may be preferably used for the formulation of pharmaceutical preparations from the point of view of chemical stability and hygroscopicity as well.
- the dihydrogen phosphate salt is strongly hygroscopic, DVS tests have shown that at a humidity of 95% its water uptake reaches 3% at room temperature, which makes this salt unfavourable from the point of view of development.
- this value is an order of magnitude lower than in the case of the dihydrogen phosphate salt, around 0.35%, due to which this salt is suitable for development purposes, without special storage conditions being prescribed.
- This mass increase in the case of the baricitinib esylate salt (2) is especially preferable, being even lower at about 0.08%, and very preferable in the case of the mesylate salt (3) at around 0.02%.
- Formulation for oral administration demands that the active substance be bioavailable.
- this bioavailability may be influenced by numerous factors, such as the solubility, stability and absorption of the given medicine in the gastrointestinal system.
- the solubility of the baricitinib base in water strongly depends on the pH value of the aqueous medium.
- the normal pH value of the stomach varies between 1.2-1.8 [Remington: The Science and Practice of Pharmacy, 20 th issue (2000, editor: A.R. Gennaro); chapter 32; C.J. Perigard: Clinical Analysis].
- the solubility results are summarised in table 8. Table 8. Results of the solubility test
- the solubility of the new salts forming the subject of the invention is preferably better than that of the dihydrogen phosphate salt known of from the patent literature.
- the subject of the invention also relates to a pharmaceutical preparation containing a therapeutically effective amount of any baricitinib salt according to the invention and, optionally, one or more excipients used in pharmaceutical formulation. Furthermore, it also relates to a method for the production of a pharmaceutical preparation, characterised by that any baricitinib salt according to the invention is mixed with a pharmaceutically acceptable carrier and, optionally, pharmaceutically acceptable excipients and then placed in galenic form.
- the subject of the invention also relates to a method for the production of the above pharmaceutical preparations, in such a way that a baricitinib salt according to the invention or a mixture of them is mixed with pharmaceutically acceptable solid or liquid diluents and/or excipients, and the mixture is placed in galenic form.
- the advantage of the invention is that the compounds according to the present invention have preferable crystalline structures with homogenous morphology. Accordingly they have preferable and reproducible characteristics from the point of view of dissolution rate, bioavailability, chemical stability, hygroscopicity and processing characteristics (filterability, drying capability, tabletability, etc.).
- the subject of the invention also relates to a method for the production of baricitinb salts, characterised by that the crystalline, anhydrous, hydrate or solvate form of formula (1) baricitinib is reacted in a suitable organic solvent with the desired organic or inorganic acid, then the salt formed is isolated.
- the salts and salt polymorphs according to the invention may be produced in a way that the baricitinib free base (1) is suspended or dissolved in an organic solvent and then reacted with the desired acid at the appropriate temperature, the crystalized salt is isolated, washed with an organic solvent if necessary and then dried at the appropriate temperature.
- any method used in the pharmaceutical industry may be used for isolating the salt that serves for separating the solid phase and the liquid phase, for example, it may be filtered under atmospheric conditions, or by using vacuum filtering, or even under pressure, and a centrifuge may even be used.
- Inorganic or organic acids may be used to produce the salts according to the invention, which may be the following: ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2-hydroxyethane sulfonic acid, fumaric acid, cyclamic acid, tartaric acid.
- the reaction may be carried out in organic solvents, such as in aliphatic alcohols with 1 to 6 carbon atoms, in straight chain or ring ethers with 1 to 5 carbon atoms, in esters with 1 to 6 carbon atoms, in open chain asymmetric or symmetric ketones, and in dipolar aprotic solvents, in addition mixtures of the listed solvents may be used, as well as mixtures and blends of the listed solvents containing water.
- organic solvents such as in aliphatic alcohols with 1 to 6 carbon atoms, in straight chain or ring ethers with 1 to 5 carbon atoms, in esters with 1 to 6 carbon atoms, in open chain asymmetric or symmetric ketones, and in dipolar aprotic solvents, in addition mixtures of the listed solvents may be used, as well as mixtures and blends of the listed solvents containing water.
- ethers, esters or alcohols with 1 to 4 carbon atoms, open chain ketones or dipolar aprotic solvents, or especially preferably diisopropyl ether, ethyl acetate, acetonitrile, methyl alcohol, 2-propanol or their mixtures, or the mixtures and blends of the listed solvents may be used in order to perform the reaction.
- the acid used to form the salts is used in a 1.0 to 3.0 mol equivalent amount, preferably in a 1.1 to 2.1 mol equivalent amount calculated for the amount of baricitinib (1).
- a preferable procedure involves that the organic acid solution is used and the salt-formation reaction is carried out at a temperature between 0 °C and the boiling point of the solvent or at the boiling point of the solvent.
- the new salts of baricitinib (1) according to the present invention may be produced by dissolving or suspending the baricitinib base (1) in a suitable solvent, preferably in a polar aprotic solvent, in an alcohol or ester with 1 to 6 carbon atoms, preferably in acetonitrile, methanol, 2-propanol or ethyl acetate, then between 0 °C and the reflux temperature of the solvent 1.0 to 3.0 mol, preferably 1.1 to 2.1 mol of acid is added, on its own or in the form of a solution. If the salt precipitates at the temperature of the addition of the acid or when cooled, after the required crystallization time the product is filtered, washed and dried. If the salt does not precipitate, the solvent is evaporated in a vacuum, and the residual material is crystalized with a suitable solvent or solvent mixture, finally the crystalline material is filtered, washed and dried.
- a suitable solvent preferably in a polar aprotic solvent, in
- the new salts according to the invention may be recrystallized in order to achieve the appropriate pharmaceutical active substance quality.
- the recrystallization is performed by dissolving the product obtained according to the above in a polar aprotic solvent, or in a mixture of a polar aprotic solvent and an alcohol with 1 to 6 carbon atoms, more preferably the dissolving is performed in acetonitrile or in a mixture of acetonitrile and methanol at boiling point, then by cooling the solution the desired salt is precipitated. The precipitated solid material is filtered, washed and dried.
- the production of the baricitinib esylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent, preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent ethanesulfonic acid made with a given solvent is added while stirring.
- the reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature.
- the precipitated crystals are filtered, washed and dried.
- the production of the baricitinib mesylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent, preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent methanesulfonic acid made with a given solvent is added while stirring.
- the reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature.
- the precipitated crystals are filtered, washed and dried.
- the production of the baricitinib besylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent, preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent benzenesulfonic acid made with a given solvent is added while stirring.
- the reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature.
- the precipitated crystals are filtered, washed and dried.
- DSC Differential scanning calorimetry
- Atmosphere N 2 current (50 mL/min) Sampling intervals
- Hermetically closed Al Examples 3, 5, 6, 7, 8 x-ray powder diffraction (XRPD) measurement conditions
- Diffusion inhibitor slit Fixed slit 1/2 °
- Diffusion inhibitor slit Programmable slit in fixed mode:
- Sample preparation The unpowdered samples are placed between Mylar sheets.
- Step gap 0.0131° 2 ⁇
- Step duration 109.650 s
- Range 1 current % RH ⁇ 95% RH
- Range 2 95% RH ⁇ 0% RH
- Range 3 0% RH ⁇ current % RH
- the reaction mixture is stirred for 3 hours at 20-22 °C, then for 1 hour at 18-20 °C.
- the precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 8.35 g (97.6%) of white coloured solid product is obtained.
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2- propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.40 g (98.2%) of a white coloured solid product is obtained.
- the sample is spectroscopically and morphologically identical to the substance produced with method "A".
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.43 g (100%) of a white coloured solid product is obtained.
- the sample is spectroscopically and morphologically identical to the substance produced with method "A".
- the reaction mixture is stirred for 3 hours at 20-22 °C, then for 1 hour at 18-20 °C.
- the precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 7.36 g (94.6%) of white coloured solid product is obtained.
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2- propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.28 g (98.4%) of a white coloured solid product is obtained.
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.28 g (98.8%) of a white coloured solid product is obtained.
- the sample is spectroscopically and morphologically identical to the substance produced with method "A".
- the precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 10.51 g (99.6%) of white coloured solid product is obtained.
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2-propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.23 g (97.8%) of a white coloured solid product is obtained.
- the sample is spectroscopically and morphologically identical to the substance produced with method "A".
- reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.23 g (97.8%) of a white coloured solid product is obtained.
- the sample is spectroscopically and morphologically identical to the substance produced with method "A".
- the reaction mixture is stirred for 2 hours at 20-22 °C.
- the precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.70 g (56.36%) of a white coloured solid product is obtained.
- the precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150- 200 mbar for 24 hours. In this way 8.28 g (96.7%) of a white coloured solid product is obtained.
- Example 7 The production of ⁇ l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ⁇ i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl ⁇ acetonitrile 2-hydroxy- ethanesulfonic acid salt (baricitinib isethionate)
- the reaction mixture is stirred at this temperature for 30 minutes, then left to cool to room temperature, and stirred for a further 2 hours.
- the precipitated solid material is filtered, then 20 ml of acetonitrile and 5 ml of methanol is added to it and heated to boiling point.
- the mixture is left to cool to room temperature and the precipitated solid material is filtered.
- the product is washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.23 g (41.8%) of a white coloured solid product is obtained.
Abstract
Novel baricitinib, {1-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-d]pirimidin-4-yl)- 1H-pyrazol-1- yl]azetidin-3-yl}acetonitrile salts are disclosed, that are suitable for use as pharmaceutical active substances. More specifically, salts of baricitinib formed with ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2-hydroxyethane sulfonic acid, fumaric acid, tartaric acid and cyclamic acid are disclosed.
Description
BARICITINIB SALTS
The field of the invention
The subject of our invention relates to novel salts of the pharmaceutical active substance baricitinib, to a method for their production, to pharmaceutical preparations containing the novel salts as well as to the use of all these in medical therapy.
The state of the art
It is known that the formula (1) { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile with international non-proprietary name baricitinib is a pharmacologically active substance developed for the treatment of rheumatoid arthritis belonging to the family of Janus kinase inhibitors.
The formula (1) baricitinib was first disclosed in international patent application number WO2009114512. The production of the baricitinib trifluoroacetate salt is described in example 1 of the patent application. The ^-NMR and LC-MS data are given. The baricitinib trifluoroacetate salt is obtained using a preparative HPLC method. It should be noted that due to the toxic nature of the trifluoracetate ion it cannot be used as the counter ion of basic pharmaceutical active substances. The same patent application also discloses the baricitinib dihydrogen phosphate salt (incorrectly called phosphate in the application), and its production is also described. The dihydrogen phosphate salt is characterised by melting point, element analysis and with FTIR, 13C-NMR, ^ NMR and LC-MS data. The patent application number WO 2015145286 describes the production of the amorphous form of the baricitinib base. The amorphous form is characterised by XRPD, DSC, TG, IR data.
Patent application number WO 2015166434 describes the crystalline form of the baricitinib base containing 3% water. The crystalline form is characterised by XRPD, DSC, TG, IR data. A brief description of the invention
In the recent past a serious demand has arisen in the pharmaceutical industry to be able to reproducibly produce pure and morphologically homogenous products. This is a basic condition in order to be able to satisfy pharmaceutical formulation demands. It is well known that the various salts and polymorphs exhibit differences in important characteristics such as solubility, chemical stability, polymorph stability, dissolution rate, bioavailability, filterability, drying capability, and tabletability.
Furthermore, from the point of view of production economy, it is exceptionally important to produce the product with a method that may be implemented on the industrial scale and that reproducibly results in a morphologically homogenous crystalline form that is free of impurities. We wished to produce a product that complies with the above conditions by producing salts.
We repeated the methods disclosed in patent application number WO 2009114512 for the production of baricitinib dihydrogen phosphate salt. Proceeding in accordance with example 61, the dihydrogen salt did not precipitate from the reaction mixture, therefore we reproduced the recipe described in example 71 as well, which is characterised by the phosphoric acid being added in two steps. The water sorption isotherms of the baricitinib dihydrogen phosphate salt produced in this way show that it is very susceptible to absorbing water, which limits its use in pharmaceutical preparations.
Therefore the objective of elaborating the invention was the production of high-purity, new baricitinib salt forms with a homogenous crystalline structure, the stability and physical- chemical characteristics of which are preferable to those of the known forms and which have chemical stability at least as good and that of the known forms, and also which may be reproducibly produced even on industrial scales.
The subject of the invention relates to new salts of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- <i]pirimidin-4-yl)-lH-pyrazol- l-yl]azetidin-3-yl}acetonitrile with international non- proprietary name baricitinib that may be used as pharmaceutical active substances and a method for their production. More specifically the subject of the invention relates to the salts of baricitinib formed with ethanesulfonic acid (2), methanesulfonic acid (3) and benzenesulfonic acid (4), hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2- hydroxyethane sulfonic acid, fumaric acid, tartaric acid and cyclamic acid.
We produced the salts of baricitinib formed with hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2-hydroxyethane sulfonic acid, fumaric acid, tartaric acid, cyclamic acid, ethanesulfonic acid (2), methanesulfonic acid (3) and benzenesulfonic acid (4).
In the case of baricitinib hydrochloride and bicyclamate salts, several polymorphic forms and their physical mixtures were produced, however, the production of neither of them could be upscaled and reproduced. Experience shows that the hydrochloride and bicyclamate salt forms and their crystalline forms exhibit a large degree of chemical instability.
In the case of the baricitinib oxalate, hydrogen fumarate and hydrogen tartrate salts, it was seen that from a crystallographic point of view these forms have a low degree of structural order and low thermodynamic stability.
The baricitinib tosylate salt form produced by us has a complex crystalline structure. The salt consists of several crystal forms, the thermodynamic stability of which may be very similar, as using the usual techniques it was not possible to achieve the desired solid phase inter- transformation and so the production of a homogenous, thermodynamically stable form. However, it was surprising to find that the salts of baricitinib produced with sulfonic acids, especially ethanesulfonic acid (2), methanesulfonic acid (3) and benzenesulfonic acid (4) are forms with homogenous crystalline structures and may be reproducibly produced.
Figures
Figure 1: The moisture sorption isotherms of baricitinib dihydrogen phosphate salt produced according to example 71 of international patent application number WO 2009114512 at 25 °C
Figure 2: The x-ray powder diffractogram of the baricitinib esylate (1: 1) salt form
Figure 3: The moisture sorption isotherms of the baricitinib esylate (1:1) salt form at 25 °C Figure 4: The x-ray powder diffractogram of the baricitinib mesylate (1: 1) salt form
Figure 5: The moisture sorption isotherms of the baricitinib mesylate (1: 1) salt form at 25 °C
Figure 6: The x-ray powder diffractogram of the baricitinib besylate (1: 1) salt form
Figure 7 The moisture sorption isotherms of the baricitinib besylate (1:1) salt form at 25 °C Figure 8: Baricitinib base and salts water adsorption isotherms at 25 °C
A detailed description of the invention
The subject of the invention relates to the salts of baricitinib formed with sulfonic acids. More specifically, the subject of the invention is:
- the baricitinib esylate (1: 1) salt,
- the baricitinib mesylate (1: 1) salt,
- the baricitinib besylate (1: 1) salt.
More specifically the subject of the invention relates to the crystalline baricitinib esylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2Θ (±0.2 °2Θ): 5.80; 9.10; 13.57; 15.30; 18.30. More specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0.2 °2Θ): 5.80; 9.10; 11.59; 13.57; 15.30; 15.93; 18.30; 19.02; 20.09; 22.05. Even more specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0.2 °2Θ): 5.80; 9.10; 9.95; 11.59; 13.24; 13.57; 15.30; 15.93; 17.46; 18.30; 19.02; 20.09; 21.06; 21.36; 22.05; 23.31; 23.57; 24.44; 24.69; 24.95; 25.37; 25.81; 26.37; 26.69; 26.88; 27.36; 28.27; 28.72; 29.32; 30.17; 30.78; 31.76; 32.22; 34.40. The characteristic x-ray powder diffractogram of this may be seen in figure 2, and the 2% or greater intensity signals are summarised in the following table 1.
Table 1: The x-ray powder diffraction data of the baricitinib esylate (1: 1) salt form
(relative intensities > 2%)
Peak 2Θ (°) d (A) Relative intensity (%)
1 5.80 15.23 13
2 9.10 9.71 56
3 9.95 8.88 5
4 11.59 7.63 8
5 13.24 6.68 5
6 13.57 6.52 18
7 15.30 5.79 45
8 15.93 5.56 32
9 17.46 5.07 4
10 18.30 4.84 100
11 19.02 4.66 20
12 20.09 4.42 25
Peak 2Θ (°) d (A) Relative intensity (%)
13 21.06 4.22 4
14 21.36 4.16 8
15 22.05 4.03 50
16 23.31 3.81 4
17 23.57 3.77 7
18 24.44 3.64 14
19 24.69 3.60 11
20 24.95 3.57 10
21 25.37 3.51 22
22 25.81 3.45 6
23 26.37 3.38 12
24 26.69 3.34 14
25 26.88 3.31 20
26 27.36 3.26 15
27 28.27 3.15 10
28 28.72 3.11 17
29 29.32 3.04 4
30 30.17 2.96 4
31 30.78 2.90 9
32 31.76 2.82 3
33 32.22 2.78 8
34 34.40 2.60 8
The moisture sorption isotherms of the baricitinib esylate (1: 1) salt form according to the invention recorded at 25 °C are presented in figure 3. It is visible that, preferably, the substance does not exhibit significant hygroscopicity.
More specifically the subject of the invention also relates to the crystalline baricitinib mesylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2Θ (±0.2 °2Θ): 5.84; 9.33; 13.92; 15.44; 18.59. More specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0.2 °2Θ): 5.84; 9.33; 11.70; 13.62; 15.44; 15.99; 18.59; 18.73; 19.23; 25.45. Even more specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0.2 °2Θ): 5.84; 9.33; 10.29; 11.70; 13.33; 13.62; 15.44; 15.99; 17.58; 18.59; 18.73; 19.23; 19.80; 20.23; 20.43; 20.66; 21.10; 21.52; 22.47; 22.54; 23.53; 23.91; 24.11; 24.50; 24.75; 25.05; 25.30; 25.45; 26.37; 26.50; 26.95; 27.45; 28.04; 28.50; 28.93; 29.53; 31.22; 31.65; 34.78. The characteristic x-ray powder diffractogram of this may be seen in figure 4, and the 1% or greater intensity signals are summarised in the following table 2.
Table 2: The x-ray powder diffraction data of the baricitinib mesylate (1: 1) salt form
(relative intensities > 1%)
Peak 2Θ (°) d (A) Relative intensity (%)
1 5.84 15.12 13
2 9.33 9.47 29
3 10.29 8.59 9
4 11.70 7.56 11
5 13.33 6.64 7
6 13.62 6.50 38
7 15.44 5.73 76
8 15.99 5.54 31
9 17.58 5.04 4
10 18.59 4.77 100
11 18.73 4.73 27
12 19.23 4.61 31
13 19.80 4.48 12
14 20.23 4.39 7
Peak 2Θ (°) d (A) Relative intensity (%)
15 20.43 4.34 10
16 20.66 4.30 6
17 21.10 4.21 4
18 21.52 4.13 6
19 22.47 3.95 23
20 22.54 3.94 21
21 23.53 3.78 3
22 23.91 3.72 12
23 24.11 3.69 2
24 24.50 3.63 12
25 24.75 3.59 32
26 25.05 3.55 12
27 25.30 3.52 20
28 25.45 3.50 65
29 26.37 3.38 9
30 26.50 3.36 19
31 26.95 3.31 38
32 27.45 3.25 42
33 28.04 3.18 5
34 28.50 3.13 9
35 28.93 3.08 32
36 29.53 3.02 3
37 31.22 2.86 12
38 31.65 2.82 6
Peak 2Θ (°) d (A) Relative intensity (%)
39 32.31 2.77 13
40 34.78 2.58 9
The moisture sorption isotherms of the baricitinib mesylate (1: 1) salt form according to the invention recorded at 25 °C are presented in figure 5. It is visible that, preferably, the substance does not exhibit significant hygroscopicity.
More specifically the subject of the invention also relates to the crystalline baricitinib besylate (1: 1) salt form the characteristic x-ray powder diffraction peaks of which are the following: 2Θ (±0.2 °2Θ): 7.19; 11.26; 12.63; 14.36; 16.51. More specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0,2 °2Θ): 7.19; 11.26; 12.63; 14.36; 16.51; 16.61; 17.66; 18.48; 20.83; 24.64. Even more specifically it may be characterised by the following x-ray powder diffraction peaks: 2Θ (±0.2 °2Θ): 7.19; 9.20; 11.26; 12.63; 14.36; 14.86; 16.51; 16.61; 16.92; 17.33; 17.66; 18.25; 18.48; 18.79; 20.15; 20.83; 21.17; 22.11; 22.39; 22.73; 24.10; 24.35; 24.64; 25.35; 25.77; 26.83; 26.99; 27.72; 27.92; 28.34; 28.99; 29.52; 29.98; 30.57; 31.32; 31.64. The characteristic x-ray powder diffractogram of this may be seen in figure 6, and the 2% or greater intensity signals are summarised in the following table 3.
Table 3: The x-ray powder diffraction data of the baricitinib besylate (1: 1) salt form
(relative intensities > 2%)
Peak 2Θ (°) d (A) Relative intensity (%)
1 7.19 12.29 70
2 9.20 9.61 8
3 11.26 7.85 40
4 12.63 7.00 45
5 14.36 6.17 55
6 14.86 5.96 10
7 16.51 5.37 89
8 16.61 5.33 35
9 16.92 5.24 11
Peak 2Θ (°) d (A) Relative intensity (%)
10 17.33 5.11 7
11 17.66 5.02 77
12 18.25 4.86 21
13 18.48 4.80 85
14 18.79 4.72 12
15 20.15 4.40 38
16 20.83 4.26 59
17 21.17 4.19 28
18 22.11 4.02 4
19 22.39 3.97 3
20 22.73 3.91 24
21 24.10 3.69 10
22 24.35 3.65 13
23 24.64 3.61 100
24 25.35 3.51 40
25 25.77 3.45 46
26 26.83 3.32 17
27 26.99 3.30 32
28 27.72 3.22 15
29 27.92 3.19 9
30 28.34 3.15 4
31 28.99 3.08 32
32 29.52 3.02 4
33 29.98 2.98 3
Peak 2Θ (°) d (A) Relative intensity (%)
34 30.57 2.92 3
35 31.32 2.85 13
36 31.64 2.83 9
The moisture sorption isotherms of the baricitinib besylate (1:1) salt form according to the invention recorded at 25 °C are presented in figure 7. It is visible that the substance is slightly more susceptible to absorbing water than the baricitinib esylate (1: 1) or the baricitinib mesylate (1: 1) salt forms according to the invention, however, from the point of view of use in a pharmaceutical preparation the hygroscopicity is still sufficiently low.
On the basis of toxicology data in the literature it can be determined that the 2.95 mg of ethanesulfonic acid, the 2.58 mg of methanesulfonic acid and the 4.25 mg of benzenesulfonic acid taken with the maximum daily dose of 10 mg of baricitinib is, preferably, just a fraction of the permitted daily amount of ethanesulfonic acid, methanesulfonic acid and benzenesulfonic acid, therefore toxicity concerns do not arise.
The thermal stress test and the forced stability test present an accelerated model of the degradation occurring in the pharmaceutical preparation during storage. The results of this forecast whether the new salts of baricitinib (1) according to the invention will be stable in pharmaceutical preparations under forced stability conditions. This preferable characteristic of the baricitinib salts according to the present invention is very important from the point of view of the formulation of the pharmaceutical preparation, its storage and the minimising of the damaging effects exerted on the human body.
The stability of the baricitinib esylate (1: 1), baricitinib mesylate (1: 1) and baricitinib besylate (1: 1) salts forming the subject of the present application was subjected to detailed tests. The baricitinib base was used as a reference.
The results of the accelerated stability test are presented in the following tables 4 to 7. The table includes the percentage amounts of the contaminants and their change, as well the water content of the samples and its change.
Table 4 The stability test data of the baricitinib base (1) used as a reference
Initial 40 °C, 70%
Storage conditions 25 °C, 90% RH 70 °C, open sample RH
6 3 6 3 6
Storage time 3 weeks
weeks weeks weeks weeks weeks
Water content
0.2 0.2 0.1 0.2 0.2 0.2 0.2 [m/m%]
Known contaminant
1 0.10 0.10 0.11 0.10 0.11 0.11 0.11
RRT=0.90 (%)
Unknown
contaminant 0.11 0.14 0.09 0.14 0.09 0.14 0.08
RRT=0.92 (%)
Known contaminant
2 0.05 - 0.08 - 0.08 - 0.09
RRT=1.06 (%)
Total 0.26 0.24 0.28 0.24 0.28 0.25 0.28
Table 5. The stability test data of baricitinib esylate (2)
Initial 40 °C, 70%
Storage conditions 25 °C, 90% RH 70 °C, open sample RH
6 3 6 3 6
Storage time 3 weeks
weeks weeks weeks weeks weeks
Water content
0.3 0.2 0.1 0.2 0.1 0.2 0.2 [m/m%]
Known contaminant
1 0.11 0.12 0.14 0.12 0,15 0.12 0.14
RRT=0.90 (%)
Unknown - - - - - - -
Initial 40 °C, 70%
Storage conditions 25 °C, 90% RH 70 °C, open sample RH
contaminant
RRT=0.92 (%)
Known contaminant
2 0.06 0.07 0.07 0.06 0.06 0.06 0.06
RRT=1.06 (%)
Total 0.17 0.19 0.21 0.18 0.21 0.18 0.20
Table 6. The stability test data of baricitinib mesylate (3)
Initial 40 °C, 70%
Storage conditions 25 °C, 90% RH 70 °C, open sample RH
6 3 6 3 6
Storage time 3 weeks
weeks weeks weeks weeks weeks
Water content
0.3 0.2 0.2 0.2 0.1 0.2 0.2 [m/m%]
Known contaminant
1 0.11 0.11 0.13 0.11 0.13 0.11 0.13
RRT=0.90 (%)
Unknown
contaminant - - - - - - -
RRT=0.92 (%)
Known contaminant
2 0.03 0.04 0.04 0.04 0.04 0.04 0.04
RRT=1.06 (%)
Total 0.14 0.15 0.17 0.15 0.17 0.15 0.17
Table 7. The stability test data of baricitinib besylate (4)
It was surprising to experience that the baricitinib salts according to the present invention were seen to be especially stable as compared to the baricitinib base (1) and the baricitinib dihydrogen phosphate salt during 3 and 6 weeks of storage under various forced conditions. An especially significant advantage of our new salts over the base (1) is that while the base contains a contaminant of unknown structure with retention of RRT=0.92, surprisingly this contaminant cannot be detected at all in the new salts (2-4) according to the invention. As a strict 0.10% limit relates to contaminants of unknown structure on the basis of pharmaceutical industry guidelines, the presence of the contaminant in this amount in the base is critical. From the data in the table it can be seen that the salts (2-4) according to the present invention can be preferably produced at a greater level of purity than the reference baricitinib base (1).
It can also be seen from the summary table of the results that the salt forms preferably did not display water absorption under various storage conditions, even when the humidity was high. Therefore the baricitinib esylate (1: 1), baricitinib mesylate (1: 1) and baricitinib besylate (1: 1)
salts may be preferably used for the formulation of pharmaceutical preparations from the point of view of chemical stability and hygroscopicity as well.
In figure 8 the moisture sorption isotherms of all the baricitinib salts according to the invention have been compared with the moisture sorption isotherms of the baricitinib dihydrogen phosphate salt that may be produced according to example 71 of international patent application number WO 2009114512 and of the baricitinib base produced according to that described in the IP.com publication number 000244270 (publication date: 27.11.2015). From the comparison of figures 1, 3, 5, 7 and 8 it can be seen that all three baricitinib salt forms according to the invention are less disposed to absorb water than the baricitinib dihydrogen phosphate salt that may be produced according to example 71 of international patent application number WO 2009114512 between 5 and 95% RH. The dihydrogen phosphate salt is strongly hygroscopic, DVS tests have shown that at a humidity of 95% its water uptake reaches 3% at room temperature, which makes this salt unfavourable from the point of view of development. At the same time, it was surprising to determine that the moisture content of none of the baricitinib salts according to the present invention reaches 0.5% at a relative humidity between 5 and 95%. Even in the case of the besylate salt (4) this value is an order of magnitude lower than in the case of the dihydrogen phosphate salt, around 0.35%, due to which this salt is suitable for development purposes, without special storage conditions being prescribed. This mass increase in the case of the baricitinib esylate salt (2) is especially preferable, being even lower at about 0.08%, and very preferable in the case of the mesylate salt (3) at around 0.02%.
Formulation for oral administration demands that the active substance be bioavailable. In the case of a preparation taken orally, this bioavailability may be influenced by numerous factors, such as the solubility, stability and absorption of the given medicine in the gastrointestinal system.
The solubility of the baricitinib base in water strongly depends on the pH value of the aqueous medium. The normal pH value of the stomach varies between 1.2-1.8 [Remington: The Science and Practice of Pharmacy, 20th issue (2000, editor: A.R. Gennaro); chapter 32; C.J. Perigard: Clinical Analysis]. The pH value of the oesophagus is 4.5 and the pH value of the small intestines is around 6.8. Therefore the solubility experiments were carried out at three different pH values in addition to distilled water (pH=l, pH=4.5 and pH=6.8). The solubility results are summarised in table 8.
Table 8. Results of the solubility test
From the summary table of the results it can be seen that the solubility data of the new salts forming the subject of the invention, i.e. baricitinib esylate (1:1), baricitinib mesylate (1: 1) and baricitinib besylate (1: 1), at pH=l are similar to the solubility values of the reference baricitinib base, significantly better at pH=6.8, and in distilled water and at pH=4.5 they are surprisingly considerably and preferably better. Similarly, the solubility of the new salts forming the subject of the invention is preferably better than that of the dihydrogen phosphate salt known of from the patent literature.
The subject of the invention also relates to a pharmaceutical preparation containing a therapeutically effective amount of any baricitinib salt according to the invention and, optionally, one or more excipients used in pharmaceutical formulation. Furthermore, it also relates to a method for the production of a pharmaceutical preparation, characterised by that any baricitinib salt according to the invention is mixed with a pharmaceutically acceptable carrier and, optionally, pharmaceutically acceptable excipients and then placed in galenic form.
The subject of the invention also relates to a method for the production of the above pharmaceutical preparations, in such a way that a baricitinib salt according to the invention or
a mixture of them is mixed with pharmaceutically acceptable solid or liquid diluents and/or excipients, and the mixture is placed in galenic form.
The advantage of the invention is that the compounds according to the present invention have preferable crystalline structures with homogenous morphology. Accordingly they have preferable and reproducible characteristics from the point of view of dissolution rate, bioavailability, chemical stability, hygroscopicity and processing characteristics (filterability, drying capability, tabletability, etc.).
The subject of the invention also relates to a method for the production of baricitinb salts, characterised by that the crystalline, anhydrous, hydrate or solvate form of formula (1) baricitinib is reacted in a suitable organic solvent with the desired organic or inorganic acid, then the salt formed is isolated.
The salts and salt polymorphs according to the invention may be produced in a way that the baricitinib free base (1) is suspended or dissolved in an organic solvent and then reacted with the desired acid at the appropriate temperature, the crystalized salt is isolated, washed with an organic solvent if necessary and then dried at the appropriate temperature.
Any method used in the pharmaceutical industry may be used for isolating the salt that serves for separating the solid phase and the liquid phase, for example, it may be filtered under atmospheric conditions, or by using vacuum filtering, or even under pressure, and a centrifuge may even be used. Inorganic or organic acids may be used to produce the salts according to the invention, which may be the following: ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2-hydroxyethane sulfonic acid, fumaric acid, cyclamic acid, tartaric acid.
The reaction may be carried out in organic solvents, such as in aliphatic alcohols with 1 to 6 carbon atoms, in straight chain or ring ethers with 1 to 5 carbon atoms, in esters with 1 to 6 carbon atoms, in open chain asymmetric or symmetric ketones, and in dipolar aprotic solvents, in addition mixtures of the listed solvents may be used, as well as mixtures and blends of the listed solvents containing water.
Preferably ethers, esters or alcohols with 1 to 4 carbon atoms, open chain ketones or dipolar aprotic solvents, or especially preferably diisopropyl ether, ethyl acetate, acetonitrile, methyl alcohol, 2-propanol or their mixtures, or the mixtures and blends of the listed solvents may be used in order to perform the reaction.
The acid used to form the salts is used in a 1.0 to 3.0 mol equivalent amount, preferably in a 1.1 to 2.1 mol equivalent amount calculated for the amount of baricitinib (1).
A preferable procedure involves that the organic acid solution is used and the salt-formation reaction is carried out at a temperature between 0 °C and the boiling point of the solvent or at the boiling point of the solvent.
The new salts of baricitinib (1) according to the present invention may be produced by dissolving or suspending the baricitinib base (1) in a suitable solvent, preferably in a polar aprotic solvent, in an alcohol or ester with 1 to 6 carbon atoms, preferably in acetonitrile, methanol, 2-propanol or ethyl acetate, then between 0 °C and the reflux temperature of the solvent 1.0 to 3.0 mol, preferably 1.1 to 2.1 mol of acid is added, on its own or in the form of a solution. If the salt precipitates at the temperature of the addition of the acid or when cooled, after the required crystallization time the product is filtered, washed and dried. If the salt does not precipitate, the solvent is evaporated in a vacuum, and the residual material is crystalized with a suitable solvent or solvent mixture, finally the crystalline material is filtered, washed and dried.
The new salts according to the invention may be recrystallized in order to achieve the appropriate pharmaceutical active substance quality. The recrystallization is performed by dissolving the product obtained according to the above in a polar aprotic solvent, or in a mixture of a polar aprotic solvent and an alcohol with 1 to 6 carbon atoms, more preferably the dissolving is performed in acetonitrile or in a mixture of acetonitrile and methanol at boiling point, then by cooling the solution the desired salt is precipitated. The precipitated solid material is filtered, washed and dried.
The production of the baricitinib esylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent, preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent ethanesulfonic acid made with a given solvent is added while stirring. The reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature. The precipitated crystals are filtered, washed and dried.
The production of the baricitinib mesylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent,
preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent methanesulfonic acid made with a given solvent is added while stirring. The reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature. The precipitated crystals are filtered, washed and dried.
The production of the baricitinib besylate (1: 1) salt form is carried out by suspending the baricitinib free base (1) in a polar aprotic, straight-chain alcohol, nitrile or ester-type solvent, preferably in acetonitrile, 2-propanol or ethyl acetate at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature, then a solution of 1.0 to 1.5 mol equivalent, preferably 1.1 mol equivalent benzenesulfonic acid made with a given solvent is added while stirring. The reaction mixture is stirred for 1 to 24 hours, preferably for 2 to 4 hours at a temperature between 0 °C and the boiling point of the solvent, preferably at room temperature. The precipitated crystals are filtered, washed and dried.
The invention is illustrated via the following examples, without limiting the invention to these examples.
EXAMPLES Measurement conditions used
NMR measurement conditions
The NMR spectra of the new salts according to the invention were recorded using the following device:
- VARIAN INOVA 500 (500 MHz)
- BRUKER AVANCE III 400 (400 MHz)
The NMR measurements of the new salts were in all cases performed in solution phase, the solvent used was deuterated dimethyl sulfoxide (DMSO-ifc).
Differential scanning calorimetry (DSC) measurement conditions
Device: TA Instruments Discovery DSC differential scanning
calorimeter
Atmosphere: N2 current (50 mL/min)
Sampling intervals
Temperature program: Room temperature - melting point 10 °C/min
Standard Al open Example 2
Sample holder: Standard Al closed Examples 1, 4, 9
Hermetically closed Al: Examples 3, 5, 6, 7, 8 x-ray powder diffraction (XRPD) measurement conditions
Device: PANalytical Empyrean X-ray powder diffractometer
Measuring mode: Transmission
X-ray tube
Type: Empyrean Long Fine Focus High Resolution tube Anode: Cu
Wavelength Ka (1.541874 A)
Focussing: line focus
Radiation source side optics
Divergence slit: Fixed slit 1/2 °
Mirror: Elliptical focussing mirror
Soller slit: 0.04 rad
Diffusion inhibitor slit: Fixed slit 1/2 °
Detector side optics
Diffusion inhibitor slit: Programmable slit in fixed mode:
Soller slit: 0.04 rad
Sample holder
Type: Reflection-transmission spinner stage
Sample rotation speed: 1 rps
Sample knife: Transmission ray blocking used
Detector
Type: PrXcel 3D 1 1 terdetektor
Detecting mode: Scanning line detector mode (ID)
Active length: 3.3473°
Sample preparation: The unpowdered samples are placed between Mylar sheets.
Measurement settings
Temperature: room temperature
Accelerating voltage: 45 kV
Anode heating current: 40 mA
Scanning: continuous gonio (Θ/Θ) scan
Measurement range: 2.0000 - 34.9964 °2Θ
Step gap: 0.0131° 2Θ
Step duration: 109.650 s
Measurement cycles: 1
Measurement time: -20 min
Dynamic vapour sorption analysis (DVS) measurement conditions
SMS DVS Advantage DVSAl-STD dynamic vapour sorption
Device:
analyser
Atmosphere: nitrogen
Total gas flow: 200 ml/min
Solvent: water
Temperature: 25 °C
Step size: 5% RH
Stability criterion: 0.002 %/min
Phases: DMDT Window: 5 min
Minimum stability time: 30 min
Maximum phase time: 360 min
Data saving frequency: 1 min
Range 1 : current % RH→ 95% RH
Measurement ranges: Range 2: 95% RH→ 0% RH
Range 3 : 0% RH→ current % RH
Measurement conditions used during the stability test
Test name Baricitinib purity test
Device type: Waters Acquity H-Class UPLC
Column type: Waters Acquity CSH CI 8; 2,1 x50 mm; 1,7 μιη
Preparation of sample solution for solubility test
With analytical precision 500 mg salt form is measured into a 20.0 ml Erlenmeyer flask. 10 ml of medium is added, then shaken for 6 hours at a rate of 100 min"1 at 37 °C. After shaking the solution is left to settle for 18 hours at 37 °C. The settled solution is filtered through a 0.45 μιη filter. 1 ml of filtered solution is diluted to 100.0 ml. Example 1
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)-lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile besylate (baricitinib besylate)
Method "A "
6.0 g (16.15 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile (baricitinib) is measured into 100 ml of acetonitrile at 20-22 °C, then while stirring a solution of 2.81 g (17.77 mmol; 1.1 equiv.) of benzenesulfonic acid made with 20 ml of acetonitrile is added to it drop by drop. The reaction mixture is stirred for 3 hours at 20-22 °C, then for 1 hour at 18-20 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 8.35 g (97.6%) of white coloured solid product is obtained.
Following this 7.6 g of raw product is dissolved in 700 ml of acetonitrile at boiling point, then the solution is left to cool to room temperature, and stirred for 1 hour. The precipitated solid material is filtered, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 6.80 g (89.3%) of white coloured solid product is obtained.
Mp.: 179.2 °C (onset).
IR (KBr): 3100, 2817, 2259, 1615, 1592, 1328.
^ NMR (DMSO-ifc, 400 MHz): 13.19 (b, 1H), 9.20 (s, 1H), 9.03 (s, 1H), 8.68 (s, 1H), 7.99
(m, 1H), 7.61 (m, 2H), 7.43 (m,lH), 7.31 (m, 3H), 4.60 (d, J=9.2 Hz, 2H), 4.30 (d, J=9.2 Hz, 2H), 3.73 (s, 3H), 3.24 (q, J=7.3 Hz, 2H), 1.25 (t, J=7.3Hz, 3H).
13C-NMR (DMSO-ifc, 100 MHz): 152.07, 148.46, 145.87, 140.54, 132.00, 130.97, 128.58, 127.81, 125.65, 116.64, 112.66, 102.87, 58.58,56.84, 43.72, 26.98, 7.61.
Element analysis calculated for the formula C22H23N7O5S2 (M 529.59):
C 49.90%; H 4.38%; N 18.51%; S 12.11%
Measured: C 50.01%; H 4.36%; N 18.47%; S 12.00%.
Method "B "
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of 2-propanol at 20- 22 °C, then while stirring a solution of 470 mg (2.96 mmol; 1.1 equiv.) of benzenesulfonic acid made with 5 ml of 2-propanol is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2- propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.40 g (98.2%) of a white coloured solid product is obtained.
The sample is spectroscopically and morphologically identical to the substance produced with method "A".
Method "C"
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of ethyl acetate at 20-22 °C, then while stirring a solution of 470 mg (2.96 mmol; 1.1 equiv.) of benzenesulfonic acid made with 5 ml of ethyl acetate is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.43 g (100%) of a white coloured solid product is obtained.
The sample is spectroscopically and morphologically identical to the substance produced with method "A".
Example 2
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)-lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile esylate (baricitinib esylate)
Method "A "
6.0 g (16.15 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-i/]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is measured into 100 ml of acetonitrile at 20-22 °C, then while stirring a solution of 1.96 g (17.77 mmol; 1.1 equiv.) of ethanesulfonic acid made with 20 ml of acetonitrile is added to it drop by drop. The reaction mixture is stirred for 3 hours at 20-22 °C, then for 1 hour at 18-20 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 7.36 g (94.6%) of white coloured solid product is obtained.
Following this 6.68 g of raw product is dissolved in 550 ml of acetonitrile at boiling point, then the solution is left to cool to room temperature, and stirred for 1 hour. The precipitated solid material is filtered, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 5.78 g (86.5%) of white coloured solid product is obtained. Mp.: 171.2 °C (onset).
IR (KBr): 2775, 2245, 1623, 1317, 1208, 1140, 1033.
^ NMR (DMSO-ifc, 400 MHz): 13.24 (b, 1H), 9.23 (s, 1H), 9.04 (s, 1H), 8.70 (s, 1H), 8.01 (m, 1H), 7.44 (m, 1H), 4.60 (d, J=9.2 Hz, 2H), 4.31 (d, J=9.3 Hz, 2H), 3.74 (s, 2H), 3.25 (q, J=7.3 Hz, 2H), 2.46 (q, J=7.4 Hz, 2H), 1.25 (t, J=7.3 Hz, 3H), 1.09 (t, J=7.4 Hz, 3H).
13C-NMR (DMSO-ifc, 100 MHz): 152.07, 144.52, 140.58, 132.08, 131.08, 116.65, 115.73, 112.64, 102.93, 58.58, 56.85, 45.38, 43.67, 26.98, 10.00, 7.62.
Element analysis calculated for the formula C18H23N7O5S2 (M 481.55):
C 44.90%; H 4.82%; N 20.36%; S 13.32%
Measured: C 45.00%; H 4.84%; N 19.87%; S 13.06%.
Method "B "
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of 2-propanol at 20- 22 °C, then while stirring a solution of 326.2 mg (2.96 mmol; 1.1 equiv.) of ethanesulfonic acid made with 5 ml of 2-propanol is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2- propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.28 g (98.4%) of a white coloured solid product is obtained.
The sample is spectroscopic ally and morphologically identical to the substance produced with method "A".
Method "C "
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-i/]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of ethyl acetate at 20-22 °C, then while stirring a solution of 326.2 mg (2.96 mmol; 1.1 equiv.) of ethanesulfonic acid made with 5 ml of ethyl acetate is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.28 g (98.8%) of a white coloured solid product is obtained.
The sample is spectroscopically and morphologically identical to the substance produced with method "A".
Example 3
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile mesylate (baricitinib mesylate)
Method "A "
8.45 g (22.75 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is measured into 150 ml of acetonitrile at 20-22 °C, then while stirring 2.40 g (25.03 mmol; 1.1 equiv.) of methanesulfonic acid is added to it drop by drop. The reaction mixture is stirred for 3 hours at 20-22 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 10.51 g (99.6%) of white coloured solid product is obtained.
Following this 9.80 g of raw product is suspended in 300 ml of acetonitrile at boiling point, then 200 ml of methanol is added to it drop by drop. The solution is left to cool to room temperature, and stirred for 1 hour. The precipitated solid material is filtered, then dried in a drying cabinet at 24 °C and at a pressure of 150-200 mbar for 24 hours. In this way 5.26 g (53.7%) of white coloured solid product is obtained.
Mp.: 220.4 °C (onset).
IR (KBr): 2251, 1625, 1320, 1221, 1151, 1036.
HNMR (DMSO-ifc, 400 MHz): 13.18 (bs, 1H), 9.21 (s, 1H), 9.02 (s, 1H), 8.68 (s, 1H), 7.99
(m, 1H), 7.42 (m, 1H), 4.59 (d, J=9.2 Hz, 2H), 4.30 (d, J=9.3 Hz, 2H), 3.25 (q, J=7.3
Hz, 2H), 2.38 (s, 3H), 1.25 (t, J=7.3 Hz, 3H).
CNMR (DMSO-ifc, 100 MHz): 152.10, 146.02, 140.56, 131.98, 130.92, 116.67, 112.68,
102.82, 58.59, 56.83, 43.68, 26.99, 7.63.
Element analysis calculated for the formula C17H21N7O5S2 (M 467.52):
C 43.67%; H 4.53%; N 20.97%; S 13.71%
Measured: C 43.77%; H 4.54%; N 20.44%; S 13.53%.
Method "B "
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of 2-propanol at 20- 22 °C, then while stirring 191 μΐ (2.96 mmol; 1.1 equiv.) of methanesulfonic acid is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed with 2-propanol on the filter, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.23 g (97.8%) of a white coloured solid product is obtained.
The sample is spectroscopically and morphologically identical to the substance produced with method "A".
Method "C"
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 15 ml of ethyl acetate at 20-22 °C, then while stirring 191 μΐ (2.96 mmol; 1.1 equiv.) methanesulfonic acid is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then the precipitated solid material is filtered, washed on the filter with ethyl acetate, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.23 g (97.8%) of a white coloured solid product is obtained.
The sample is spectroscopically and morphologically identical to the substance produced with method "A".
Example 4
The production of formula (I) { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l-yl]azetidin-3-yl}acetonitrile hydrochloric acid salt (baricitinib hydrochloride)
1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol-l-yl]azetidin-3-yl}acetonitrile of formula (I) (baricitinib) is measured into 15 ml of methanol at 20-22 °C, then while stirring 2.86 ml (1.1 equiv.) of a 1 M methanolic HC1 solution is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C. The precipitated solid material is filtered, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.00 g (91.1%) of a white coloured solid product is obtained.
Element analysis calculated for the formula C16H18CIN7O2S (M 407.88):
C 47.12%; H 4.45%; N 24.04%; S 7.86%; CI 8.69%.
Measured: C 47.03%; H 4.44%; N 23.22%; S 7.84%; CI 8.43%.
Following this 0.80 g of raw product is dissolved in 15 ml of acetonitrile at boiling point, then 7 ml of methanol is added to it drop by drop at this temperature. Following this the solution is left to cool to room temperature, and stirred for two hours. The precipitated solid material is filtered, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.32 g (40.6%) of white coloured solid product is obtained. Mp.: 240.8 °C (peak maximum)
IR (KBr): 2393, 1612, 1592, 1346, 1143.
^ NMR (DMSO-ifc, 400 MHz): 13.42 (b, 1H), 9.47 (s, 1H), 8.98 (s, 1H), 8.94 (s, 1H), 8.03
(m, 1H), 7.51 (m, 1H), 4.60 (d,J=9.3 Hz, 2H), 4.33 (d, J=9.3 Hz, 2H), 3.77 (s, 2H), 3.28 (q, J=7.3 Hz, 2H), 1.26 (t, J=7.3 Hz, 3H).
13C-NMR (DMSO-ifc, 100 MHz): 152.03, 145.02, 143.80, 141.04, 132.60, 131.35, 116.63, 115.09, 112.41, 103.22, 58.60, 56.88, 43.66, 26.97, 7.62.
Element analysis calculated for the formula C16H18CIN7O2S (M 407.88):
C 47.12%; H 4.45%; N 24.04%; S 7.86%; CI 8.69%.
Measured: C 47.25%; H 4.36%; N 23.68%; S 7.85%; CI 8.37%.
Example 5
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile oxalate (baricitinib oxalate) 1.00 g (2.69 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is measured into 40 ml of acetonitrile at 20-22 °C, then while stirring a solution of 0.27 g (2.96 mmol; 1.1 equiv.) of oxalic acid made with 10 ml of acetonitrile is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.70 g (56.36%) of a white coloured solid product is obtained.
Mp.: 184.1 °C (peak maximum).
IR (KBr): 3113, 2656, 2259, 1625, 1583, 1345, 1142.
^ NMR (DMSO-ifc, 400 MHz): 12.20 (bs, 1H), 8.95 (s, 1H), 8.74 (s, 1H), 8.50 (s, 1H), 7.65 (dd, Jl=2.4 Hz, J2=3.5 Hz, 1H), 7.11 (dd, Jl=1.5 Hz, J2=3.5 Hz, 1H), 4.62 (d, J=9.2 Hz, 2H), 4.27 (d, J=9.3 Hz, 2H), 3.71 (s, 2H), 3.25 (q, J=7.4 Hz, 2H), 1.26 (t, J=7.3 Hz, 3H).
13C-NMR (DMSO-ifc, 100 MHz): 161.27, 152.39, 150.95, 149.41, 140.13, 129.88, 127.26, 122.23, 116.86, 113.25, 100.23, 58.75, 56.30, 43.56, 27.04, 7.64.
Element analysis calculated for the formula C18H19N7O6S (M 461.45):
C 46.85%; H 4.15%; N 21.25%; S 6.95%
Measured: C 46.72%; H 4.17%; N 21.16%; S 6.97%.
Example 6
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile tosylate (baricitinib tosylate)
5.85 g (15.57 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is measured into 150 ml of acetonitrile at 20-22 °C, then while stirring a mixture of 1.98 g (17.33 mmol; 1.1 equiv.) of p- toluenesulfonic acid made with 20 ml of acetonitrile is added to it drop by drop. The reaction mixture is stirred for 3 hours at 20-22 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in a drying cabinet at 24 °C and at a pressure of 150- 200 mbar for 24 hours. In this way 8.28 g (96.7%) of a white coloured solid product is obtained.
Mp.: 221,2 °C (peak maximum).
IR (KBr): 3062, 2250, 2811, 1595, 1317, 1149.
XH-NMR (DMSO-ifc, 400 MHz): 13.24 (b, 1H), 9.22 (s, 1H), 9.04 (s, 1H), 8.69 (s, 1H), 8.01
(m, 1H), 7.49 (~d, J=8.0 Hz, 2H), 7.45 (m, 1H), 7.12 (~d, J=7.9 Hz, 2H), 4.60 (d, J=9.2 Hz, 2H), 4.30 (d, J=9.2 Hz, 2H), 3.25 (q. J=7.3 Hz, 2H), 2.29 (s, 3H), 1.25 (t,
J=7.3 Hz, 3H).
13C-NMR (DMSO-ife, 100 MHz): 152.09, 146.03, 140.55, 131.96, 130.89, 116.66, 112.68,
102.80, 58.59, 56.82, 43.69, 26.98, 7.62.
Element analysis calculated for the formula C23H25N7O5S2 (M 543.62):
C 50.82%; H 4.64%; N 18.04%; S 11.80%
Measured: C 50.83%; H 4.59%; N 17.96%; S 11.83%.
Example 7
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile 2-hydroxy- ethanesulfonic acid salt (baricitinib isethionate)
1.00 g (2,.69 mmol) { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 30 ml of acetonitrile at 20-22 °C, then while stirring a solution of 0.47 g (2.97 mmol; 1.1 mol equiv.) of 2-hydroxy- ethanesulfonic acid made with 5 ml of acetonitrile is added to it drop by drop. The reaction mixture is stirred for 4 hours at 20-22 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 1.18 g (90.8%) of a white coloured solid product is obtained. Mp.: 142,9 °C (onset).
IR (KBr): 3455, 3111, 2671, 2249, 1628, 1595, 1158, 1029, 1322..
^ NMR (DMSO-ifc, 400 MHz): 13.31 (b, 1H), 9.25 (s, 1H), 9.06 (s, 1H), 8.72 (s, 1H), 8.04
(m, 1H), 7.47 (m, 1H), 4.60 (d, J=9.2 Hz, 2H), 4.32 (d, J=9.2 Hz, 2H), 3.74 (s, 2H), 3.66 (t, J=6.8 Hz, 2H), 3.26 (q, J=7.3 Hz, 2H), 2.69 (t, J=6.8 Hz, 2H), 1.26 (t, J=7.3
Hz, 3H).
13C-NMR (DMSO-ifc, 100 MHz): 152.05, 145.31, 144.03, 140.62, 132.28, 131.42, 116.64,
115.13, 112.60, 103.18, 58.59, 57.88, 56.91, 53.87, 43.73, 26.98, 7.63
Element analysis calculated for the formula C18H23N7O6S2 (M 497.55):
C 43.45%; H 4.66%; N 19.71%; S 12.89%
Measured: C 43.36%; H 4.63%; N 19.48%; S 12.99%.
Example 8
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile fumarate (baricitinib hydrogen fumarate)
3.00 g (8.08 mmol) { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)- lH-pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is dissolved in 130 ml of acetonitrile at boiling point, then while stirring 1.03 g (8.89 mmol; 1.1 equiv.) of fumaric acid is added to it. The reaction mixture is stirred at this temperature for 30 minutes, then left to cool to room temperature, and stirred for a further 1 hour. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 3.81 g (96.7%) of a white coloured solid product is obtained. Mp.: 206,5 °C (peak maximum).
IR (KBr): 3120, 2536, 1703, 1584, 1275, 1141.
^ NMR (DMSO-ifc, 400 MHz): 13.16 (b, 2H), 12.16 (bs, 1H), 8.94 (s, 1H), 8.72 (s, 1H),
8.48 (s, 1H), 7.63 (dd, Jl=2.5 Hz, J2=3.4 Hz, 1H), 7.09 (dd, Jl=1.6 Hz, J2=3.5 Hz, 1H), 6.64 (s, 2H), 4.61 (d, J=9.2 Hz, 2H), 4.24 (d, J=9.2 Hz, 2H), 3.70 (s, 2H), 3.23 (q, J=7.4 Hz, 2H), 1.25 (t, J=7.3 Hz, 3H).
13C-NMR (DMSO-ife, 100 MHz): 166.16, 152.39, 151.09, 149.55, 140.09, 134.17, 129.78,
127.12, 122.41, 116.83, 113.25, 100.12, 58.73, 56.25, 43.55, 27.07, 7.62.
Element analysis calculated for the formula C20H21N7O6S (M 487.49):
C 49.28%; H 4.34%; N 20.11%; S 6.58%
Measured: C 49.52%; H 4.32%; N 20.41%; S 6.61%.
Example 9
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile dicyclamate (baricitinib dicyclamate) 0.50 g (1.35 mmol) of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3- ]pirimidin-4-yl)-lH- pyrazol- l-yl]azetidin-3-yl}acetonitrile (baricitinib) is dissolved in 20 ml of acetonitrile at boiling point, then while stirring 0.27 g (1.48 mmol; 1.1 equiv.) of cyclamic acid is added to it. The reaction mixture is stirred at this temperature for 30 minutes, then left to cool to room temperature, and stirred for a further 2 hours. The precipitated solid material is filtered, then 20 ml of acetonitrile and 5 ml of methanol is added to it and heated to boiling point. The mixture is left to cool to room temperature and the precipitated solid material is filtered. The product is washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.23 g (41.8%) of a white coloured solid product is obtained.
Mp.: 217,5 °C (peak maximum).
IR (KBr): 3422, 1628, 1599, 1329, 1137, 1063, 617.
XH-NMR (DMSO-ifc, 400 MHz): 12.20 (bs, 1H), 8.95 (s, 1H), 8.72 (s, 1H), 8.49 (s, 1H), 7.69
(b), 7.64 (m, 1H), 7.10 (m, 1H), 4.60 (d, J=9.3 Hz, 2H), 4.25 (d, J=9.4 Hz, 2H), 3.70 (s, 2H), 3.26 (q, J=7.4 Hz, 2H), 2.95 (m, 2x lH), 1.87 (m, 2x2H), 1.62 (m, 2x2H), 1.59 (m, 2x lH), 1.23 (m, 3H + 2x4H), 1.10 (2x lH).
13C-NMR (DMSO-ifc, 100 MHz): 152.37, 151.02, 149.48, 140.08, 129.82, 127.18, 122.33,
116.84, 113.23, 100.16, 58.72, 56.25, 49.51, 43.48, 30.52, 27.01, 24.72, 23.91, 7.62.
Measured: C 44.29%; H 6.44%; N 15.88%.
Example 10
The production of { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile tartarate (baricitinib hydrogen tartarate)
0.5 g (1.35 mmol) { l-(ethylsulphonyl)-3-[4-(7H-pyrrolo[2,3-<i]pirimidin-4-yl)- lH-pyrazol-l- yl]azetidin-3-yl}acetonitrile (baricitinib) is suspended in 22 ml of acetonitrile at 20-22 °C, then while stirring a solution of 0.22 g (1.48 mmol; 1.1 mol equiv.) of D,L-tartaric acid made with 3 ml of water is added to it drop by drop. The reaction mixture is stirred for 2 hours at 20-22 °C, then evaporated until dry. 25 ml of acetonitrile is added to the residue, and then stirred for 1 hour at 20-22 °C. The precipitated solid material is filtered, washed on the filter with acetonitrile, then dried in the air at atmospheric pressure until constant weight is achieved. In this way 0.1 mg (33.3%) of a white coloured solid product is obtained.
IR (KBr): 3142, 2258, 1694, 1631, 1599, 1350, 1328, 1137.
^ NMR (DMSO-ifc, 400 MHz): 12.57 (b, 1H), 12.15 (bs, 1H), 8.93 (s, 1H), 8.71 (s, 1H),
8.48 (s, 1H), 7.63 (dd, Jl=2.4 Hz, J2=3.5 Hz, 1H), 7.09 (dd, Jl=1.6 Hz, J2=3.5 Hz, 1H), 4.61 (d, J=9.2 Hz, 2H), 4.31 (s, 2H), 4.24 (d, J=9.2 Hz, 2H), 3.70 (s, 2H), 3.24 (q, J=7.4 Hz, 2H), 1.25 (t, J=7.3 Hz, 3H).
13C-NMR (DMSO-ife, 100 MHz): 173.32, 152.38, 151.09, 149.55, 140.09, 129.80, 127.14,
122.41, 116.85, 113.24, 100.13, 72.33, 58.73, 56.25, 43.49, 27.02, 7.62.
Element analysis calculated for the formula C20H23N7O8S (M 521.51):
C 46.06%; H 4.45%; N 18.80%; S 6.15%
Measured: C 44.41%; H 4.56%; N 17.96%; S 6.21%.
Claims
1. Salts of bancitinib formed with sulfonic acid, as well as their amorphous and crystalline forms, hydrates and solvates.
2. The baricitinib salt according to claim 1, which is a salt formed with ethanesulfonic acid, methanesulfonic acid or benzenesulfonic acid.
3. The crystalline baricitinib esylate (1 : 1) salt according to claim 2 the characteristic x- ray powder diffraction peaks of which are the following: 2Θ (±0.2° 2Θ): 5.80; 9.10; 13.57; 15.30; 18.30.
4. The crystalline baricitinib mesylate (1 : 1) salt according to claim 2 the characteristic x- ray powder diffraction peaks of which are the following: 2Θ (±0.2° 2Θ): 5.84; 9.33; 13.92; 15.44; 18.59.
5. The crystalline baricitinib besylate (1 : 1) salt according to claim 2 the characteristic x- ray powder diffraction peaks of which are the following: 2Θ (±0.2° 2Θ): 7.19; 11.26; 12.63; 14.36; 16.51.
6. Method for the production of a baricitinib salt according to any of claims 1 to 5, characterised by that baricitinib base is reacted with an organic acid in an organic solvent or in a mixture of an organic solvent and water, then the baricitinib salt formed is isolated.
7. Pharmaceutical preparation that contains a baricitinib salt according to any of claims 1 to 5.
8. The compound according to any of claims 1 to 5 for use in the treatment or prevention of rheumatoid arthritis, psoriasis or diabetic nephropathy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1600030 | 2016-01-21 | ||
HU1600030A HU230931B1 (en) | 2016-01-21 | 2016-01-21 | Baricitinib salts |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017125772A1 true WO2017125772A1 (en) | 2017-07-27 |
Family
ID=89992056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2017/050001 WO2017125772A1 (en) | 2016-01-21 | 2017-01-19 | Baricitinib salts |
Country Status (2)
Country | Link |
---|---|
HU (1) | HU230931B1 (en) |
WO (1) | WO2017125772A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020072870A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Co-crystal forms of baricitinib |
WO2020163431A1 (en) * | 2019-02-05 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Crystalline solid forms of baricitinib |
CN111999400A (en) * | 2020-07-15 | 2020-11-27 | 安徽联创生物医药股份有限公司 | Method for separating and determining impurities of bulk drugs of baricitinib by using HPLC (high performance liquid chromatography) |
US11066403B2 (en) | 2017-06-07 | 2021-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Solid form of azetidine derivative and preparation method therefor and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009114512A1 (en) * | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
-
2016
- 2016-01-21 HU HU1600030A patent/HU230931B1/en unknown
-
2017
- 2017-01-19 WO PCT/HU2017/050001 patent/WO2017125772A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009114512A1 (en) * | 2008-03-11 | 2009-09-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066403B2 (en) | 2017-06-07 | 2021-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Solid form of azetidine derivative and preparation method therefor and use thereof |
WO2020072870A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Co-crystal forms of baricitinib |
WO2020163431A1 (en) * | 2019-02-05 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Crystalline solid forms of baricitinib |
CN111999400A (en) * | 2020-07-15 | 2020-11-27 | 安徽联创生物医药股份有限公司 | Method for separating and determining impurities of bulk drugs of baricitinib by using HPLC (high performance liquid chromatography) |
CN111999400B (en) * | 2020-07-15 | 2022-07-01 | 安徽联创生物医药股份有限公司 | Method for separating and determining impurities of bulk drugs of baricitinib by using HPLC (high performance liquid chromatography) |
Also Published As
Publication number | Publication date |
---|---|
HU230931B1 (en) | 2019-04-29 |
HUP1600030A2 (en) | 2017-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019137699A (en) | Crystalline polymorphs of free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
JP7199739B2 (en) | Salts and crystal forms of positive allosteric modulators of GABAA | |
EP2753603B1 (en) | Polymorphic form of pridopidine hydrochloride | |
WO2017125772A1 (en) | Baricitinib salts | |
US20200199125A1 (en) | Solid state forms of palbociclib dimesylate | |
US20220235039A1 (en) | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide | |
US9856270B2 (en) | Dolutegravir salts | |
EA030142B1 (en) | Dasatinib salts | |
US11230559B2 (en) | Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate | |
EP3368527B1 (en) | Palbociclib tosylate | |
EP3650444B1 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
EP3473623B1 (en) | Crystal forms of nbi-98854, preparation method therefor and use thereof | |
WO2018007842A1 (en) | Pimavanserin salts useful for the production of a pharmaceutical preparation | |
EP2729460B1 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride | |
CN114773211B (en) | Meglumine salt crystal form, preparation method and application thereof | |
US20220119415A1 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
US20230348433A1 (en) | Polymorphs of [2-(1h-indol-3-yl)-1h-imidazol-4-yl](3,4,5-trimethoxy)methanone and its salts | |
US20230286998A1 (en) | Succinate salts of octahydrothienoquinoline compound and crystals thereof | |
US20240116925A1 (en) | Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof | |
WO2017093773A1 (en) | New polymorphic and solvate form of idelalisib | |
US20220098206A1 (en) | Solid state forms of oclacitinib maleate | |
WO2017029408A1 (en) | Solid state forms of sofosbuvir | |
CN117377658A (en) | Process for preparing quinoline derivative compounds | |
CN116199668A (en) | Evobretinib compound salt and preparation method thereof | |
EP2154137A1 (en) | Crystalline form of moxifloxacin base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17741141 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17741141 Country of ref document: EP Kind code of ref document: A1 |